About Javeri Equity Derivatives Mutual Funds IPO Corporate Info Research Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  CASH FLOW
Cash Flow      
Glaxosmithkline Pharmaceuticals Ltd.
BSE Code 500660
ISIN Demat INE159A01016
Book Value 98.85
NSE Code GLAXO
Dividend Yield % 1.40
Market Cap 387008.08
P/E 57.86
EPS 39.49
Face Value 10  
(Rs. in Millions)
ParticularsMar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Profit Before Tax9526.518374.8724700.437223.336469.92
Adjustment-461.40-408.56-16369.31-252.54141.98
Changes In working Capital645.47-390.181348.90630.32435.93
Cash Flow after changes in Working Capital9710.587576.149680.037601.117047.83
Cash Flow from Operating Activities5789.374879.368197.925948.654909.73
Cash Flow from Investing Activities149.668051.95-4196.604075.68-631.03
Cash Flow from Financing Activities-5614.97-15441.78-5242.42-6955.60-4276.22
Net Cash Inflow / Outflow324.06-2510.48-1241.113068.742.49
Opening Cash & Cash Equivalents297.432807.914049.02980.28977.79
Cash & Cash Equivalent on Amalgamation / Take over / Merger00000
Cash & Cash Equivalent of Subsidiaries under liquidations00000
Translation adjustment on reserves / op cash balalces frgn subsidiaries00000
Effect of Foreign Exchange Fluctuations00000
Closing Cash & Cash Equivalent621.49297.432807.914049.02980.28
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA
Publishing of investor charter information | Annexure A – Investor charter of brokers |
Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.